Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: JEB who wrote (1000)	6/9/1999 7:41:00 PM
From: P.M.Freedman	Read Replies (2) \| Respond to of 1686

The "cash" reported in 10Q, as always, included Biogen's holdings on stocks, bonds, options, and so on. The numbers were based on the market values on the last day of the ending quarter. Those repurchased BGEN shares were still able to be accounted as Biogen's cash holdings. As a one-product company, Biogen's incomes may be very volatile. This quarter, they may get similar numbers as last one. However, considering the market for Avonex is nearly saturated, it will be very hard for Biogen to cook the numbers that the Street is expecting in the future.